■无铂间期(PFI)是从基于铂的化疗结束到复发之日。如果PFI>6个月,以铂类为基础的化疗再激发被考虑;然而,聚腺苷5'-二磷酸-核糖聚合酶(PARP)抑制剂维持治疗后的疗效尚不清楚.本研究旨在检查PARP抑制剂治疗后铂类化疗再激发的疗效。
■我们回顾性评估了PARP抑制剂维持治疗的PFI≥6个月的卵巢癌患者,接受铂类化疗。PARP抑制剂治疗的持续时间,对随后的铂类化疗再激发的最佳反应,并从病历中收集临床特征。根据RECIST1.1评估肿瘤反应。使用Spearman相关系数计算相关性。
■在纳入的10名患者中,七个(70%)在初次化疗后接受了PARP抑制剂,3人(30%)接受铂类敏感复发化疗。1和5例患者携带种系BRCA1和BRCA野生型突变,分别,两个具有同源重组能力。中位PFI为303.5(182-602)天,PARP抑制剂治疗持续时间为249(147-570)天。铂类化疗再激发疗效完全和部分缓解,疾病稳定在一个(10%),六(60%),和三名(30%)患者,分别。PARP抑制剂治疗的持续时间越长,对铂类药物的反应更好(Spearman相关系数0.284,p=0.0288)。
■铂类化疗再激发对于铂类敏感疾病患者是合理的,使用6个月的传统PFI截止值,即使使用维持PARP抑制剂获得PFI。
UNASSIGNED: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy
rechallenge is considered; however, its efficacy after poly adenosine 5\'-diphosphate-ribose polymerase (PARP) inhibitor maintenance therapy is unknown. This study aimed to examine the efficacy of a platinum-based chemotherapy
rechallenge after PARP inhibitor therapy.
UNASSIGNED: We retrospectively evaluated patients with ovarian cancer with a PFI≥6 months with PARP inhibitor maintenance therapy, receiving platinum-based chemotherapy. Duration of PARP inhibitor therapy, best response to subsequent platinum chemotherapy
rechallenge, and clinical characteristics were collected from medical records. Tumor response was assessed according to RECIST 1.1. Correlations were calculated using Spearman\'s correlation coefficients.
UNASSIGNED: Among the 10 included patients, seven (70 %) received PARP inhibitors after primary chemotherapy, and three (30 %) received chemotherapy for platinum-sensitive relapse. One and five patients harbored a germline BRCA1 and BRCA wild-type mutations, respectively, and two had homologous recombination proficiency. The median PFI was 303.5 (182-602) days, and PARP inhibitor therapy duration was 249 (147-570) days. Platinum chemotherapy
rechallenge efficacy was complete and partial response and stable disease in one (10 %), six (60 %), and three (30 %) patients, respectively. The longer the duration of PARP inhibitor treatment, better the response to platinum agents (Spearman correlation coefficient 0.284, p = 0.0288).
UNASSIGNED: Platinum-based chemotherapy
rechallenge is reasonable for patients with platinum-sensitive disease, using the traditional PFI cutoff of 6 months, even when the PFI is obtained with a maintenance PARP inhibitor.